First Choice Neurology

Michelle Ferreira, DO

Michelle Ferreira, DO

Michelle Ferreira, DO

Dr. Michelle Ferreira is a Board-Certified Neurologist who practices in the South Palm Beach / North Broward Counties area. She is fellowship-trained in Movement Disorders and subspecializes in Parkinson’s disease, Essential Tremors, Botulinum Toxins, Functional Neurological Disorders, and Gait Disorders. Dr. Ferreira received her medical degree from Nova Southeastern University. She completed her Neurology Residency at the University of Miami, and her Movement Disorders Fellowship at Cleveland Clinic Florida.

Currently, she is a Neurology Professor and instructs-mentors Neurology Residents at Palmetto General and Larkin Community Hospitals in Miami, as well as medical students in Nova Southeastern University College of Osteopathic Medicine in Ft. Lauderdale, Florida. Dr. Michelle Ferreira evaluates and treats patients with Parkinson’s Disease, Essential Tremors, Cervical Dystonia, Limb Spasticity, Lewy Body Dementia, Alzheimer’s Dementia, Migraines, Neuropathies, Fibromyalgia, Multiple Sclerosis, Strokes, Trigeminal Neuralgia, and Epilepsy. She is a member of the American Academy of Neurology, Movement Disorders Society, American Medical Association, and Florida Medical Osteopathic Association.


Schedule a Telemedicine Appointment
(You must first call the office at (561) 962-1508 to schedule an appointment. Please do not click on the link and enter the waiting room unless you have a scheduled appointment).

Telemedicine Appointment

Services Provided in Office
Botulinum toxins for Neurological Disorders (Botox, Dysport, Myobloc, Xeomin)
Neuropsychological testing
Nerve Conduction Studies (NCS)
Electromyogram (EMG)
Electroencephalogram (EEG)
Deep Brain Stimulation for Parkinson’s and Essential Tremors
Small Fiber Biopsy
Cannabis (Medical Marijuana) for the treatment of Neurological Disorders
Gene Testing
Infusion Therapies in Neurology

BS in Biology, Nova Southeastern University, Ft. Lauderdale, FL 2002
Doctorate in Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL 2006
Neurology Residency, University of Miami, Miami, FL 2011
Movement Disorders Fellowship, Cleveland Clinic, FL 2012

Board Certifications
American Board of Psychiatry and Neurology (Neurology)

Research & Clinical Trials
Genzyme OBS13434-A Prospective, Multicenter, Observational, Post-Authorization Study To Evaluate The Long-Term Safety Profile Of Lemtrada Treatment In Patients With Relapsing Forms Of Multiple Sclerosis.

Avanir 15-AVP-786-301-A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Safety And Tolerability Of AVP-786 For The Treatment Of Agitation In Patient With Dementia Of The Alzheimer’s Type.

Luitpold 1VIT13037 – A double-blind, multi-center, randomized, placebo-controlled study to investigate the efficacy and safety of Injectafer (Ferric Carboxymaltose) in the treatment of Restless Legs Syndrome (RLS) Bayer Healthcare/Xcenda 17942 – Impact of the BETACONNECT auto-injector on BETASERON therapy adherence and patient satisfaction

Amgen 20150133 Evidera A-16821 – A prospective observational study to evaluate tolerability and outcomes of prophylactic therapies in Migraines BioDelivery BDSI BNX-401 – Prospective Evaluation of Treatment Satisfaction with Buprenorphine/Naloxone Buccal Film in Opioid-Dependent Subjects

Biogen POP 105MS401 – Plegridy Observational Program to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS

Hoffman La-Roche VANILLA BP28420E – A multi-center, randomized, double-blind, 12-week parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of RO5285119 in individuals with Autism spectrum disorders (ASD)

Novartis EXPAND CBAF312A2304 – Evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis

Novartis PASSAGE FTY720D3403 – Safety Study in Patients with Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

PET STUDY DCA-2 – Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship between Scan Status and Cognitive Decline in Alzheimer’s Patients

UCB Bioscience SP0993 – Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older Novartis

PREFERMS CFTY720DUS09 –Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease-Modifying Therapy in Patients with Relapsing-Remitting Multiple Sclerosis

PET STUDY DCA-1 – Potential of Florbetapir F18 PET to Inform Clinical Diagnosis and Management of Alzheimer’s Patients with Progressive Cognitive Decline

Ipsen A-TL 52150-56 Anchor-DC – DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia

Accepts New Patients

List of insurance plans accepted

English, Spanish

Google Reviews
Read her Google Reviews

5350 W. Hillsboro Blvd., Suite 108
Coconut Creek, FL 33073
Phone: (561) 962-1508
Fax: (561) 962-1564

Monday - Thursday: 8:30 a.m. - 4:30 p.m.
Friday: 8:30 a.m. - 1:30 p.m. (no lunch break)

Hospital Affiliations
West Boca Medical Center
Coral Springs Medical Center




Michelle Ferreira, DO is a neurologist located in Coconut Creek, Florida. You can contact her office at (561) 962-1508.

  • Michelle Ferreira, DO
Translate »
Skip to content